

REMARKS

Currently claims 1-10 are pending. Claims 1-2, 5-6, and 9-10 are cancelled herein. Claims 11-26 are newly introduced. Accordingly, claims 3-4, 7-8, and 11-26 are presented for examination. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,


John L. Lemancowicz
Attorney for Applicant
Registration No. 37,380

Date: May 5, 2006
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8247
Facsimile: 919-483-7988